Liver Metastases Treatment Market Size, Share | Report 2023-2032
The global liver metastases treatment market was surpassed at USD 1.34 billion in 2022 and is expected to hit around USD 2.7 billion by 2032, growing at a CAGR of 7.25% from 2023 to 2032.
Key Pointers
Report Scope of the Liver Metastases Treatment Market
| Report Coverage | Details |
| Market Size in 2022 | USD 1.34 billion |
| Revenue Forecast by 2032 | USD 2.7 billion |
| Growth rate from 2023 to 2032 | CAGR of 7.25% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | F. Hoffmann-La Roche Ltd.; AstraZeneca; Bayer AG; Eli Lilly and Company; Ono Pharmaceutical; Pfizer, Inc.; Bristol-Myers Squibb Company; Cadila Pharmaceuticals Ltd. |
This can be attributed to the rising incidence of the target disease. According to the National Library of Medicine, approximately 5.14% of total cancer cases were diagnosed with synchronous metastatic hepatocellular cancer in 2020. Breast cancer and colorectal cancer are the most common sites for liver metastases in young women and men. The rising number of cases is thus expected to boost demand for drugs over the forecast period. Moreover, growing research in the field positively contributes to market growth. Several government and non-profit organizations are actively involved in research activities. For instance, the National Cancer Institute is running a program P01 focusing on understanding the common mechanism involved in the development of liver metastases using disparate tumor models. Successful completion of the study is expected to boost the development of novel diagnostics and medicines for treatment in the coming years.
However, the lack of proper availability of diagnostic and treatment methods for liver metastases is expected to slow down the market growth worldwide. Currently, the diagnosis of colorectal cancer liver metastases is performed with help of focal biopsy and imaging examinations but the lack of sensitivity in imaging diagnosis of hepatocellular carcinoma consequently restrains the market growth. Therefore, it is necessary to develop appropriate and novel methods for diagnostics.
Radiation therapy, ablation treatments, and surgery are some of the most commonly used treatments for metastasized hepatocellular carcinoma. The availability and wide usage of these treatments are expected to restrain the market growth of the liver metastases treatment drugs market.
Regional Insights
North America dominated the global market in terms of the revenue share of 40.92% in 2022. The favorable reimbursement policies for stage 4 cancers and the availability of advanced treatment options improve access to treatment. There are around 140,000 people with liver metastases annually in the U.S. Additionally, in May 2020, the U.S. FDA approved atezolizumab in combination with bevacizumab for the treatment of patients suffering from advanced metastatic hepatocellular carcinoma. The approval and adoption of such targeted therapy agents are expected to drive market growth.
Asia Pacific is expected to expand at the highest CAGR during the forecast period owing to the increase in target disease prevalence. The increasing healthcare expenditure and insurance coverage in the region is further expected to aid market growth. Due to a lack of effective screening practices and access to healthcare in this region cancers are mostly diagnosed at advanced stages. This represents a key growth opportunity for the market.
Liver Metastases Treatment Market Segmentations:
| By Treatment Type | By Primary Cancer | By Distribution Channel |
|
Chemotherapy Targeted Therapy Immunotherapy |
Colorectal Cancer Breast Cancer |
Hospital Pharmacies Specialty Pharmacies |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Treatment Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Liver Metastases Treatment Market
5.1. COVID-19 Landscape: Liver Metastases Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Liver Metastases Treatment Market, By Treatment Type
8.1. Liver Metastases Treatment Market, by Treatment Type, 2023-2032
8.1.1 Chemotherapy
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Targeted Therapy
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Immunotherapy
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Liver Metastases Treatment Market, By Primary Cancer
9.1. Liver Metastases Treatment Market, by Primary Cancer, 2023-2032
9.1.1. Colorectal Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Breast Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Liver Metastases Treatment Market, By Distribution Channel
10.1. Liver Metastases Treatment Market, by Distribution Channel, 2023-2032
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Specialty Pharmacies
10.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Liver Metastases Treatment Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Primary Cancer (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AstraZeneca
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bayer AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eli Lilly and Company
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Ono Pharmaceutical
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Pfizer, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Bristol-Myers Squibb Company
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Cadila Pharmaceuticals Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers